Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia

Lena Napolitano, MD (Other)
Overall Status
Recruiting ID
GlycoMimetics Incorporated (Industry)

Study Details

Study Description

Brief Summary

The purpose of this study is to find out whether the drug uproleselan can help patients with severe COVID-19 pneumonia. Investigators will study both the side effects of the drug and assess if the drug will help patients recover more quickly and slow down the progression of acute respiratory failure.

Condition or Disease Intervention/Treatment Phase
Phase 1/Phase 2

Detailed Description

Soluble E-selectin is a significant biomarker for ARDS. Soluble E-selectin also has pro-inflammatory properties further releasing cytokines and promoting its synthesis and the continued influx of neutrophils. Small molecule glycomimetic antagonists of E-selectin (rivipansel and uproleselan) are 500- to 1000-fold more potent inhibitors of E-selectin and have shown activity and no measurable toxicity in human clinical trials for other indications. Treatment with these E-selectin inhibitors reduced the levels of soluble E-selectin in the bloodstream which occurs during recovery of ARDS. Thus antagonists of E-selectin which include glycomimetic antagonists and more specifically, rivipansel (GMI-1070) and uproleselan (GMI-1271), may be used to treat COVID-19 patients with respiratory symptoms that may lead to ARDS

Primary Objective:

Safety of uproleselan in patients with severe COVID-19 pneumonia.

Secondary Objectives:

To evaluate if treatment with uproleselan administered intravenously in addition to the best available therapy according to institutional guidelines is able to reduce the progression of acute respiratory failure, in patients with severe COVID-19 pneumonia.

  • To evaluate proportion of patients alive and free of respiratory failure through Day 28

  • To evaluate overall survival and all-cause mortality at day 15 and 28.

  • To evaluate changes in the COVID ordinal outcomes scale.

  • To assess adverse events to evaluate the safety of uproleselan.

  • To assess ventilator-free days, ICU-free days, oxygen, vasopressor free days.

  • To evaluate changes in D-dimer.

Exploratory Objectives:
  • To examine the correlation of plasma soluble E-selectin concentrations with clinical outcomes.

  • To examine the correlations of other biomarkers of interest with clinical outcome.

Study Design

Study Type:
Anticipated Enrollment :
15 participants
Intervention Model:
Single Group Assignment
Intervention Model Description:
This is a prospective, interventional, single-arm, open label trial, with 1:1 matched de-identified retrospective control cohort.This is a prospective, interventional, single-arm, open label trial, with 1:1 matched de-identified retrospective control cohort.
None (Open Label)
Primary Purpose:
Official Title:
A Pilot Study to Assess the Safety, Tolerability and Efficacy of Selectin Inhibitor Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia
Actual Study Start Date :
Nov 12, 2021
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Nov 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Uproleselan

Uproleselan injection is a sterile solution for IV administration, supplied in single-dose vials at a concentration of 50 mg/mL.

Drug: Uproleselan
Uproleselan should be administered intravenously (IV) into a peripheral line, a central catheter, or a peripherally inserted central line catheter (PICC). Infusion should take place at a steady rate over a period of 20 minutes ±2 minutes using a syringe pump or IV pump.

Outcome Measures

Primary Outcome Measures

  1. Safety of Uproleselan - as measured by serious adverse events [Up to 28 days]

    Descriptive statistics will be calculated for quantitative safety data

  2. Safety of Uproleselan- as measured by frequency of serious adverse events [Up to 28 days]

    Frequency counts will be compiled for classification of qualitative safety data.

Secondary Outcome Measures

  1. Change in the progression to acute respiratory failure for Patients with a baseline PaO2/FiO2 >= 200 [Enrollment, 15 days]

  2. Proportion of patients alive who are free of respiratory failure [Up to 28 days]

  3. All-cause mortality [Up to 28 days]

  4. Time to change oxygenation [Up to 28 days]

    Change must be for 48 hours Increase in PaO2/FiO2 of 50 (or greater) compared to the nadir of PaO2/FiO2 indicates improvement in oxygenation

  5. Number of patients requiring mechanical ventilation [Up to 28 days]

    if not on mechanical ventilation at study entry.

  6. Change in the World Health Organization (WHO) COVID-19, "8-point ordinal scale" [Enrollment, day 28]

    WHO COVID-19, "8-point ordinal scale" has a range of 1-8 with higher numbers indicating a more severe disease.

  7. Duration of hospitalization [Up to 28 days]

  8. Duration of ICU care [Up to 28 days]

  9. Toxicity assessment (including incidence of grade 3-5 hemorrhagic events) [Up to 28 days]

  10. Change in D-dimer [Enrollment, up to day 28]

  11. Change in IL-6:IL-10 ratios [Enrollment, up to day 28]

  12. Number of free days [Day 28]

    Free Days include: oxygen, ventilator, vasopressor, ICU, and Hospitalization

Eligibility Criteria


Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Documented COVID-19 pneumonia: defined as upper respiratory tract specimen (nasopharyngeal swab (NPS) or viral throat swab) positive for COVID-19 and/or imaging at computed tomography scan suggestive of COVID-19 pneumonia.

  • Confirmed coronavirus (SARS-CoV-2) (positive real-time reverse transcription polymerase chain reaction test (RT-PCR) for SARS-CoV-2 within 72 hours) enrolled ≤ 48 hours of need for supplemental oxygen.

  • Currently hospitalized requiring supplemental oxygen.

  • Have severe COVID-19 according to the World Health Organization (WHO) Interim Guidance with confirmation by real-time RT-PCR assay. The enrollment criteria with one of the following: respiratory distress, respiratory rate (RR) ≥30 beats/min; oxygen saturation level less than 93% in resting state; or partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg.

  • Willing and able to participate in all required evaluations and procedures.

Exclusion Criteria:
  • In the opinion of at least two investigators, unlikely to survive for >48 hours from screening.

  • Severe chronic respiratory disease (e.g. Chronic obstructive pulmonary disease or other) requiring supplemental oxygen and/or having required mechanical ventilation pre-COVID-19 infection.

  • Concurrent enrollment in a COVID related interventional drug trial. Use of remdesivir, steroids, and convalescent plasma are permitted along with other standard of care therapies for COVID.37

  • Currently on invasive mechanical ventilation.

  • Hypotension defined as systolic blood pressure < 90 mmHg on two sequential readings at least 4 hours apart.

  • Total Bilirubin ≤ 3 x upper limit of normal (ULN), Creatinine Clearance ≥ 30 mL/min/1.73m2.

  • Pregnant or breastfeeding.

  • Known diagnosis of an acute thrombosis on admission.

  • Concurrent dual antithrombotic therapy (aspirin or P2Y12 inhibitor plus anticoagulation to treat deep venous thrombosis or pulmonary embolism (single antiplatelet or anticoagulant agent at prophylactic dose is permitted).

  • Concomitant use of thrombolytic therapy.

  • Concomitant therapeutic systemic anticoagulant therapy (e.g. heparin, warfarin, direct thrombin inhibitors and direct factor Xa inhibitors). As per NIH Guidelines: Hospitalized adults with COVID-19 should receive Venous thromboembolism (VTE) prophylaxis per the standard of care for other hospitalized adults (AIII). Anticoagulant or antiplatelet therapy should not be used to prevent arterial thrombosis outside of the usual standard of care for patients without COVID-19 (AIII);

  • History of recent major bleeding, defined in accordance with the criteria of the International Society on Thrombosis and Hemostasis (ISTH).

  • History of bleeding disorder thought to impose excessive bleeding risk as per investigator discretion

  • Hemodynamic instability, defined as inability to maintain mean arterial pressure.

  • Hypersensitivity to the active substance or to any of the excipients of uproleselan.

  • Any physical examination findings and/or history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study

Contacts and Locations


Site City State Country Postal Code
1 The University of Michigan Ann Arbor Michigan United States 48109

Sponsors and Collaborators

  • Lena Napolitano, MD
  • GlycoMimetics Incorporated


  • Principal Investigator: Lena Napolitano, MD, University of Michigan

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Lena Napolitano, MD, Medical Director and Professor of Surgery, University of Michigan Identifier:
Other Study ID Numbers:
  • HUM00195034
First Posted:
Sep 27, 2021
Last Update Posted:
Dec 8, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by Lena Napolitano, MD, Medical Director and Professor of Surgery, University of Michigan
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 8, 2021